Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN S FLITMAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1023018223
CMS profile
91804
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,942.46

204 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,823.42 201
Education $119.04 3

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN S FLITMAN

NPI 1023018223 · CMS profile ID 91804

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023018223?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN S FLITMAN, NPI 1023018223, CMS profile ID 91804. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023018223?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEPHEN S FLITMAN, NPI 1023018223, CMS profile ID 91804. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023018223?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEPHEN S FLITMAN, NPI 1023018223, CMS profile ID 91804, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1023018223?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

204 matching records · $4,942.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 204 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 204.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $6.9107/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864053 CMS
CATALYST PHARMACEUTICALS, INC. $97.0607/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144446964 CMS
Eisai Inc. $22.5807/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110782630 CMS
ABBVIE INC. $5.3507/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103737007 CMS
Lundbeck LLC $6.5307/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145915783 CMS
Neurocrine Biosciences, Inc. $32.1307/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150822607 CMS
Novartis Pharmaceuticals Corporation $19.8507/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864033 CMS
Novartis Pharmaceuticals Corporation $8.4207/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864031 CMS
Celgene Corporation $22.2106/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101168344 CMS
Eisai Inc. $11.4706/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110782632 CMS
ABBVIE INC. $29.3606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103737005 CMS
Novartis Pharmaceuticals Corporation $7.1106/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864029 CMS
UCB, Inc. $0.7606/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143057208 CMS
UCB, Inc. $28.4506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143057210 CMS
ABBVIE INC. $9.7606/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103737001 CMS
ABBVIE INC. $24.2306/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103737003 CMS
ACADIA Pharmaceuticals Inc $7.0606/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147969582 CMS
Eisai Inc. $123.5106/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110782626 CMS
Sumitomo Pharma America, Inc. $16.9406/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148851623 CMS
Otsuka America Pharmaceutical, Inc. $22.4606/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118893004 CMS
Lundbeck LLC $10.9606/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145915781 CMS
ABBVIE INC. $2.8606/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103736999 CMS
UCB, Inc. $0.7105/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143057204 CMS
UCB, Inc. $38.6005/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143057206 CMS
ABBVIE INC. $9.4105/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103736997 CMS
Eisai Inc. $10.3905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110782634 CMS
Inspire Medical Systems, Inc. $92.8005/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148054246 CMS
Ipsen Biopharmaceuticals, Inc $32.3605/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091959907 CMS
Novartis Pharmaceuticals Corporation $19.1705/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864003 CMS
ARGENX US, INC. $27.4405/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142106169 CMS
Novartis Pharmaceuticals Corporation $7.2205/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864007 CMS
Novartis Pharmaceuticals Corporation $0.4705/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864011 CMS
EMD Serono, Inc. $128.2105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120249519 CMS
Neurocrine Biosciences, Inc. $31.7105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150823217 CMS
PFIZER INC. $20.0905/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131498317 CMS
SK Life Science, Inc. $18.7605/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154111325 CMS
Axsome Therapeutics, Inc. $14.6705/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148322210 CMS
EMD Serono, Inc. $23.7005/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120240925 CMS
Lilly USA, LLC $27.8505/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135404360 CMS
Eisai Inc. $26.1904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110782636 CMS
Otsuka America Pharmaceutical, Inc. $19.9204/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118893002 CMS
ABBVIE INC. $8.1404/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103736995 CMS
Novartis Pharmaceuticals Corporation $6.5804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864001 CMS
Grifols USA, LLC $24.5404/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124734011 CMS
Biogen, Inc. $25.5404/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104854370 CMS
Lundbeck LLC $20.0904/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145915779 CMS
Novartis Pharmaceuticals Corporation $0.7504/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864005 CMS
Novartis Pharmaceuticals Corporation $19.2204/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086864009 CMS
E.R. Squibb & Sons, L.L.C. $125.0004/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101654584 CMS
UCB, Inc. $3.1404/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143057200 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,405.30 19
PY2020 $776.36 43
PY2021 $1,825.12 77
PY2022 $4,245.66 188
PY2023 $5,138.61 223
PY2024 $4,942.46 204
PY2025 $6,054.74 235

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $402,554.25 26
PY2024 Principal investigator $501,130.29 29
PY2023 Recipient $300.00 1
PY2023 Principal investigator $525,586.48 48
PY2022 Recipient $399.00 2
PY2022 Principal investigator $393,922.22 55
PY2021 Recipient $72.00 1
PY2021 Principal investigator $379,199.21 47
PY2020 Principal investigator $1,739,471.45 84
PY2019 Principal investigator $402,868.10 94

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $25,260.00 12/29/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423071
Principal investigator 1 Janssen Research & Development, LLC $2,283.00 12/22/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423087
Principal investigator 1 Genentech, Inc. $2,554.00 12/04/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211685628
Principal investigator 1 Janssen Research & Development, LLC $20,208.00 11/13/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423093
Principal investigator 1 UCB SA $652.71 11/13/2025 Non-covered Recipient Entity
XENOSCIENCE
An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures No dispute reported 06/30/2026 1246659330
Principal investigator 1 UCB SA $55.78 11/13/2025 Non-covered Recipient Entity
XENOSCIENCE
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246659332
Principal investigator 1 Janssen Research & Development, LLC $12,101.00 10/23/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423076
Principal investigator 1 Genentech, Inc. $2,213.00 10/15/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211685636
Principal investigator 1 UCB SA $9,503.50 09/11/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246656656
Principal investigator 1 Genentech, Inc. $2,511.00 09/03/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211685634
Principal investigator 1 ABBVIE INC. $1,952.36 08/19/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202505157
Principal investigator 1 Genentech, Inc. $2,554.00 08/15/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211685626
Principal investigator 1 ABBVIE INC. $2,273.59 08/13/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202504501
Principal investigator 1 Janssen Research & Development, LLC $17,739.00 08/11/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423082
Principal investigator 1 Genentech, Inc. $5,386.00 06/03/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211685622
Principal investigator 1 Genentech, Inc. $2,213.00 05/13/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211685632
Principal investigator 1 Janssen Research & Development, LLC $52,204.00 03/24/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175423101
Principal investigator 1 UCB SA $24,138.68 03/10/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246659537
Principal investigator 1 UCB SA $7,863.00 02/28/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246659092
Principal investigator 1 Genentech, Inc. $10,201.00 02/20/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211685624
Principal investigator 1 Genentech, Inc. $2,511.00 02/18/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211685630
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,046.54 01/31/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190306155
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,715.59 01/27/2025 Non-covered Recipient Entity
Xenoscience
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235991608
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $139,388.40 01/24/2025 Non-covered Recipient Entity
Xenoscience
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235991606
Principal investigator 1 UCB SA $4,326.00 01/17/2025 Non-covered Recipient Entity
XENOSCIENCE INC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246659400
Principal investigator 1 ABBVIE INC. $2,700.10 01/16/2025 Non-covered Recipient Entity
XENOSCIENCE INC
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202439766